CYP19A1 and neoplasm: We did not detect mutational differences based on targeted sequencing of 51 cancer-related genes in any of our models, which included ESR1. This further corroborates that resistance to endocrine treatment is not only tumor dependent but drug dependent, since it has now been established that ESR1 mutations are a frequent mechanism of resistance to aromatase inhibition [26, 27].